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Background: Multidrug-resistant organisms (MDRO) are a worldwide problem. International migration and travel
facilitate the spread of MDRO. Therefore the goal of our study was to assess the risk of influx of MDRO from patients
transferred to one of Central Europe’s largest hospitals from abroad.
Methods: A mono-centre study was conducted. All patients transferred from other countries were screened; additional
data was collected on comorbidities, etc. Presence of carbapenemases of multidrug-resistant Gram-negatives was
confirmed by PCR. The association between length of stay, being colonized and/or infected by a MDRO, country of
origin, diagnosis and other factors was assessed by binomial regression analyses.
Results: From 2012 to 2013, one fifth of all patients were colonized with MDRO (Methicillin-resistant Staphylococcus
aureus [4.1 %], Vancomycin-resistant Enterococci [2.9 %], multidrug-resistant Gram-negatives [12.8 %] and extensively
drug-resistant Gram-negatives [3.4 %]). The Gram-negatives carried a variety of carbapenemases including OXA, VIM,
KPC and NDM. The length of stay was significantly prolonged by 77.2 % in patients colonized with a MDRO, compared
to those not colonized (p<0.0001).
Conclusions: Country-to-Country transfer of patients to European hospitals represents a high risk of introduction of
MDRO and infection control specialists should endorse containment and screening measures.
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Multidrug-resistant organisms (MDRO) are a worldwide
problem and the speed at which resistance rates are in-
creasing is worrying. Antibiotic resistance crosses inter-
national boundaries and spreads easily between
continents [1]. Surveillance systems such as the
European Antimicrobial Resistance Surveillance System
network report a continuing increase in antimicrobial
resistance. International travel and patient transfers from
hospitals located in high-prevalence regions to hospitals
in low-prevalence regions facilitate the spread of MDRO.
This condition triggers the introduction and establish-
ment of MDRO into previously unaffected or less af-
fected regions [2]. Methicillin-resistant Staphylococcus
aureus (MRSA), for example, is a major cause of* Correspondence: Nico.Mutters@med.uni-heidelberg.de
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wide [3]. It appears, however, to be regionally very differ-
ently distributed. While prevalence rates in some
countries such as the Netherlands or Scandinavian coun-
tries are very low, MRSA are highly prevalent in the
USA, Japan and Greece [4–6]. In addition, the epidemi-
ology of vancomycin-resistant Enterococci (VRE) exhibits
a remarkable geographic diversity and variable tempor-
ary trends [6–9]. Though the situation in Gram-positives
appears to be rather stable, the situation in multidrug-
resistant Gram-negatives (MDR-GN) is disquieting. The
extensive use of broad-spectrum antibiotics has trig-
gered the proliferation of highly resistant Gram-negative
organisms [10]. In the last decade these organisms have
spread over the whole world and can be found (sporad-
ically or endemic) almost everywhere now [11–13].
The identification of patients carrying these MDRO is
of utmost importance for infection control. Screening
and pre-emptive contact isolation in single rooms, how-
ever, is also very costly. In addition, being colonizede is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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has an influence on morbidity and mortality as well.
This could result in an increased length of stay (LOS)
and higher in-hospital costs. We therefore conducted
a study to estimate the risk of influx of MDRO from
country-to-country transfer of patients.Methods
Study population
Only patients transferred from abroad to Heidelberg
University Hospital (HUH) were included. HUH is a one
of Germany’s largest hospitals with 2,000 beds and
90,000 in-patients per year. HUH provides a full range
of medical and surgical services, including transplant-
ation programmes, and is one of the leading medical
centres in Europe. Approximately 500 patients per year
are transferred from other countries to HUH, mainly
from the Middle East.
Start of the study was the 15th of July 2012; endpoint
was the 15th of September 2013. Patients were included
and screened if they spent 48 h or longer in a hospital
abroad (i.e. outside of Germany) within 14 days prior to
admission to HUH and if they had an expected stay of
24 h or longer at HUH. All patients were pre-emptively
isolated in single rooms until negative screening results
were obtained. The screening regimen included nasal,
rectal and if applicable wound or stoma swabs (eSwab,
Copan). In addition, clinical specimens were also
checked for MDRO. Infection with an MDRO was de-
fined as patients with clinical MDRO infection. Criteria
were based on CDC/NHSN definitions for healthcare-
assocoiated infections (http://www.cdc.gov/HAI/infec-
tionTypes.html). We retrospectively collected additional
data including: Patients’ age and gender, country of ori-
gin and/or residency, diagnosis related groups (DRG),
type of hospital ward, LOS, type of specimen sent for
microbiological testing, and type of pathogen isolated.Table 1 Country of origin of screened patients
Area code Number / Percent
Middle East 238 / 57.5
Non-EU-Europe 74 / 17.9
EU 54 / 13.0
Africa 35 / 8.5
Asia 10 / 2.4
Americasa 2 / 0.5
Australiaa 1 / 0.2
Total 414
EU (including EFTA [European Free Trade Association] countries Switzerland &
Norway); Non-EU-Europe (including Russia)
a:excluded from the logistic regression analysisMicrobiological methods
Swabs were inoculated on Columbia 5 % sheep blood
agar plate (BD) and chromogenic plates for MRSA
detection (ChromAgar MRSA II, BD), for ESBL/
MDR-GN detection (chromID ESBL, bioMerieux), and
for VRE detection (Chromagar VRE, Mast Diagnos-
tica); incubated aerobically for 48 h at 36 °C.
Columbia-sheep blood agar was used as growth con-
trol. If growth on chromogenic plates was detected,
identification by matrix-assisted laser desorption
ionization-time-of-flight mass spectrometry (Bruker,
Germany), as described elsewhere, was performed
[14]. Susceptibility-testing was performed by VITEK2
(bioMerieux) according to EUCAST criteria. Presence
of resistence genes was confirmed by multiplex RT-
PCR; mecA, femB for MRSA, vanA, vanB for VRE,
and various carbapenemase resistance genes for
MDR-GN as described elsewhere [15].Classification
MDR-GN were classified as multidrug-resistant (MDR)
and extensively drug-resistant (XDR) as described else-
where [16].Spa-typing
Spa typing was performed on each of the MRSA isolates
as described elsewhere [17].Statistics
For descriptive purposes, arithmetic mean value,
standard deviation, median, interquartile range, and
cumulative frequencies were calculated as appropriate.
The LOS follows a zero inflated distribution. There-
fore we performed negative binomial regression to as-
sess the influence of colonization with MDRO and
other factors on LOS. Two different models were fit-
ted to patients with information on diagnosis
(n = 343). The first model contained being colonized,
age and main diagnosis of the patient. The diagnoses
were included due to the obvious influence of severity
of underlying disease on the LOS. The second model
contained being colonized or infected with VRE,
MRSA, MDR-GN or XDR-GN, age, and main diagno-
sis. To evaluate possible risk factors of being colo-
nized logistic regression analysis was performed,
including the country areas of Africa, Asia, the Mid-
dle East, Non-EU Europe and EU-Europe. The model
included age, grouped DRG diagnoses, and the afore-
mentioned country areas. P values of ≤0.05 were
regarded as statistically significant. Statistical analysis
was performed using SAS Software (Version 9.2, SAS,
Inc., Cary, NC, USA).
Table 2 Distribution of multidrug–resistance among isolates of colonized patients
Species No. (%) of isolates No. (%) of MDR–GN No. (%) XDR–GN No. and type of Carbapenemase in XDR–GN
Escherichia coli 42 (40.4) 39 (65) 3 (21.4) 1 none
1 NDM–1
1 KPC
MRSA 18 (17.3) N/A N/A N/A
Klebsiella pneumoniae 18 (17.3) 14 (23.3) 4 (28.6) 2 none
1 NDM–1
1 OXA–48
VRE (all E. faecium) 12 (11.5) N/A N/A N/A
Pseudomonas aeruginosa 6 (5.8) 3 (5) 3 (21.4) 2 none
1 VIM–1
Acinetobacter baumanii 3 (2.9) 0 (0) 3 (21.4) 3 OXA–23
Enterobacter cloacae 3 (2.9) 2 (3.3) 1 (7.1) 1 VIM–4
Proteus mirabilis 1 (1.0) 1 (1.7) 0 (0) N/A
Klebsiella oxytoca 1 (1.0) 1 (1.7) 0 (0) N/A
total 104 (100) 60 (100) 14 (100) 9
N/A not applicable, MRSA methicillin–resistant Staphylococcus aureus, VRE vancomycin–resistant Enterococci, NDM–1 New Delhi metallo–beta–lactamase 1, KPC
Klebsiella pneumoniae carbapenemase, OXA–23/48 oxacillinase group beta–lactamase 23/48, VIM–1/4 Verona integron–encoded metallo–beta–lactamase 1/4
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At HUH, all MDRO strains are routinely collected for
disease surveillance and outbreak detection. The
current study thus is descriptive of a bacterial collec-
tion and microbiological characteristics could only be
combined with the sex, age, clinical outcome,
hospitalization, and travel history for the patients
from which the strains were isolated. Additionally,Table 3 Influence of colonization status on LOS (Model 1) and Influ
Model 1
Parameter IRR 95 % CI
Colonized 1.772 [1.324; 2.371]





Age 0.995 [0.990; 1.001]
Diagnosis
related groups a
Surgical diseases 1.573 [0.702; 3.526]
Mild internal diseases 0.499 [0.274; 0.909]
Internal medical diseases (all others) 0.727 [0.404; 1.310]
Hereditary genetic disorders 0.920 [0.493; 1.718]
Malignancies 0.945 [0.578; 1.547]
Infection 1.079 [0.582; 2.000]
aTrauma defined as reference; IRR incidence rate ratio, CI confidence intervaldata collected from patients with negative screening
results was anonymised and restricted to sex, age,
clinical outcome, hospitalization, and travel history.
Ethical approval was therefore not required. Also, the
German Act relating to the control of communicable
diseases obliges HUH to monitor the MDRO on a regular
basis (Infektionsschutzgesetz; http://www.gesetze-im-
internet.de/ifsg/). For these reasons, consent to analyzeence of specific MDRO on LOS (Model 2)
Model 2
P value IRR 95 % CI P value
<0.001 – – –
0.033 – – –
– 2.882 [1.573; 5.280] <0.001
– 1.343 [0.801; 2.252] 0.264
– 1.738 [1.254; 2.411] <0.001
– 1.338 [0.700; 2.561] 0.379
0.122 0.994 [0.988; 1.000] 0.052
0.271 1.122 [0.519; 2.424] 0.771
0.023 0.370 [0.213; 0.643] <0.001
0.2891 0.523 [0.308; 0.890] 0.017
0.794 0.629 [0.354; 1.118] 0.114
0.823 0.679 [0.443; 1.041] 0.076
0.810 0.783 [0.446; 1.376] 0.396
Table 4 Influence of region of origin on colonization status
Effect Odds ratio 95 % CI P value
Country Area (Reference: EU)
Africa 2.493 [0.785; 7.914 ] 0.121
Asia 0.833 [0.088; 7.869] 0.873
Middle East 2.366 [0.980; 5.715] 0.056
Non-EU-Europe 1.411 [0.489; 4.077] 0.524
Age 1.012 [0.999; 1.025] 0.064
Diagnosis related groups a
Surgical diseases 0.938 [0.100; 8.799] 0.956
Mild internal diseases 1.758 [0.500; 6.184] 0.379
Internal medical diseases (all
others)
1.220 [0.322; 4.619] 0.769
Hereditary genetic disorders 1.737 [0.435; 6.925] 0.434
Malignancies 2.856 [1.200; 6.798] 0.017




aNo diagnosis (none) defined as reference; CI: confidence interval
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tained from the patients.
Results
Demographic data
The mean age of all screened patients was 42.0 years
(±23.1 SD); 59.9 % were males. The majority came
from the Middle East (57.5 %), followed by Non-EU-
Europe (17.9 %), EU-Europe (13.0 %), and Africa
(8.5 %) (Table 1). Of all countries, patients most fre-
quently came from Saudi Arabia (15.9 %), Russia
(13.5 %), and Kuwait (10.1 %). Most common diag-
noses at admission were solid organ malignancies
(43.4 %), hereditary genetic disorders (9.9 %), acute
(9.0 %) and chronic (8.5 %) internal medical diseases,
and infections (7.6 %).
Microbiological results
Eighty-seven of 414 patients were colonized with
MDRO (MRSA [4.1 %], VRE [2.9 %] or MDR-GN
[12.8 %] and XDR-GN [3.4 %]. The majority (83.9 %,
n = 73/87) was colonized with only one bacterial spe-
cies, while 16.1 % (n = 14/87) were colonized with ei-
ther two or more different MDRO. Of all isolated
Gram-negatives, 81.1 % (n = 60/74) were MDR-GN,
and 18.9 % XDR-GN, respectively. The XDR-GN car-
ried various carbapenemases from different classes.
Detailed information on the pathogens is listed in
table 2. One third (26/87; 29.9 %) of the patients was
diagnosed with an infection caused by a MDRO upon
admission. The most frequent infections were wound
infections and urinary tract infections, accounting for38.5 % (n = 10/26) and 38.5 % (n = 10/26), respect-
ively; followed by intra-abdominal infections 19.2 %
(5/26) and catheter related infections 3.8 % (1/26).
The most frequent MDRO causing infections were 53.8 %
MDR-GN (n = 14/26), 19.2 % XDR-GN (n = 5/26), 19.2 %
MRSA (n = 5/26), and 7.7 % VRE (n = 2/26). The type of
swabs obtained for specimen screening were 48.0 % nasal,
45.8 % rectal, 5.0 % wound and 1.2 % stoma.
Spa typing
In total, spa typing resolved 12 distinct spa types for
the collected MRSA strains (t002, t003, t024, t030,
t037, t044, t127, t304, t502, t688, t3343, t3379). One
patient was colonized with MRSA strains of three
different spa types (t127, t304, t3343). Two of the
MRSA isolates belonged to the clonal complex (CC)
5, which includes the Rhine-Hesse MRSA prototype
and is prevalent in the area where HUH is located.
Additionally, two MRSA strains belonged to the spa
type t044, representing the major European cMRSA
clone ST80. The majority of the collected MRSA-
isolates (83 %) belonged to low prevalence spa types
with local prevalence rates below 1.5 %.
Regression analysis
Influence of colonization status on length of stay
The median LOS for all patients was 10 days (inter
quartile range (IQR) = 3–20), and 14 days (IQR: 6–23)
when including patients with underlying diseases as
classified in DRG registry. LOS was prolonged by
77.2 % in colonized patients (Incidence rate ratio
(IRR) = 1.78, p < 0.001) compared to uncolonized pa-
tients adjusting for diagnose groups and age. Colo-
nized trauma patients had the longest prolongation of
LOS compared to all other colonized patients
(125.0 %, IRR = 2.25, p = 0.033). VRE or MDR-GN
positive patients were associated with statistically sig-
nificantly longer LOS (VRE: IRR = 2.9, p<0.001; MDR-
GN: IRR = 1.7, p<0.001) (Table 3). The models were
run including patients that had more than one isolate,
since excluding them did not change the parameter
estimates, nor improve the model fit.
Influence of region of origin on colonization status
Of all 414 patients included in the study, 3 were excluded
from the logistic regression analysis since patients from
the Americas and Australia were all uncolonized and their
numbers were too low to be included. The model was
adjusted for diagnose groups and age. Patients being
transferred from Africa (odds ratio [OR]: 2.5, 95 %
confidence interval [CI]: 0.8-7.9, p < 0.12) and the
Middle East (OR: 2.4, 95 % CI: 1.0-5.7, p<0.06) had
the highest risk of being colonized with a MDRO,
followed by patients from Non-EU countries (OR:
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from Asia (OR: 0.8, 95 % CI: 0.1-7.9, p<0.9) on the
other hand, had a lower risk of being colonized with
an MDRO compared to patients from the EU. How-
ever, the results did not reach statistical significance
(Table 4).Discussion
We screened all patients transferred from abroad for the
presence of MDRO and collected additional clinical and
demographic data to assess the impact of MDRO
colonization and infection on the individual and the
risk of influx of MDRO into large university hospitals.
The profile of HUH is representative of other large
university hospitals. The analyzed data show that a
considerable proportion of patients transferred from
abroad are colonized with MDRO, mainly with MDR-
and XDR-GN. The proportion of colonization, com-
pared to patients from other hospitals in Germany,
was equal with regards to VRE (2.9 % vs. 2.9 %),
while it was superior with regards to all other
MDROs [MRSA (4.1 % vs. 2.4 %), MDR-GN (12.8 %
vs. 2.2 %), XDR-GN (3.4 % vs. 0.3 %)].
Of all Gram-negatives 18.9 % were XDR-GN
(n = 14/74) carrying various carbapenemases of dif-
ferent classes including OXA-48, VIM-1, KPC and
NDM-1 (Table 2). The carbapenemases carrying
strains were mainly Enterobacteriaceae, such as E.
coli and K. pneumoniae, which are the main reser-
voir species for NDM, KPC, and OXA-48 carbapene-
mases worldwide [13]. Patients carrying XDR-GNs
repeatedly act as index patients, leading to outbreaks
when transferred from high prevalence areas [18,
19]. In addition, infections with MDR-GN or XDR-
GN are associated with worse clinical outcome and
prolonged LOS [20–22]. Not only infections, but also
colonizations with MDRO can have an impact on
clinical outcome and can result in prolonged LOS
[20, 23]. In some patients, being colonized also in-
creases the risk of developing an infection with the
same MDRO [24, 25]. Our results are concordant
with these findings. Being infected or colonized with
a MDRO increased the LOS significantly and consid-
erably prolonged the duration of the hospital stay.
The most substantial and statistically significant in-
crease in LOS was due to MDR-GN and VRE. The
prevalence of VRE in our study, however, was lowest
among all MDRO and the overall impact of MDR-
GN was therefore much higher. Especially E. coli,
with an incidence more than twice as high as any
other isolated microorganism in this study, had a
major impact. The advantage of our study compared
to others investigating the impact of colonization ofMDRO on LOS [26], is our adjustment for the se-
verity of underlying illnesses.
The present study also has some minor limitations.
Our results might overestimate the prevalence rates of
MDRO in the different regions, since patients trans-
ferred to a university hospital are usually sicker than
those treated in smaller regional hospitals. In addition,
our study population consisted of patients who previ-
ously had contact with hospitals in their home country,
thus having an intrinsic increased risk of being colonized
with a MDRO. As we only included patients transferred
from abroad, we cannot entirely exclude the, however
unlikely, possibility that those patients had been to Ger-
man hospitals in earlier years. Nevertheless, these are
exactly the kind of patients that are transferred to large
University Hospitals from abroad and probably reflect
the prevalence rates that infection control specialists in
Western countries have to expect. The external validity
of our results might only be hampered by the fact that
57.5 % of all patients came from the Middle East. Thus,
results might differ in hospitals where the majority of
foreign patients come from other areas.
The low MRSA rates in our study, however, might be
influenced by the fact that most of the included patients
came from the Middle East and Non-EU Europe and
only few came from Asia or the Americas. In fact, the
highest MRSA rates worldwide are found in North
America and Japan [6]. Spa typing resolved that our col-
lected MRSA strains consisted of highly diverse spa
types and only four of all MRSA positive patients had
spa types (CC5 and ST-80) also present in the local en-
demic lineages. Thus, the majority of MRSA strains from
international patients are highly diverse and not usually
found in the local European environment.
Conclusions
Our data show that a considerable proportion of trans-
ferred patients are colonized with MDRO, mainly with
MDR- and XDR-GN, which carry a variety of different
carbapenemases. Infections with MDRO occurred in ap-
proximately one-third of all colonized patients. LOS was
significantly prolonged in all colonized patients. In sum-
mary, country-to-country transfer of patients to large uni-
versity hospitals represents a risk of introduction of
MDRO. We would like to emphasize that infection con-
trol specialists should maintain vigilance, endorse contain-
ment and screening measures, and receive transferred
patients in an area of the hospital equipped to manage iso-
lation for MDRO [2].
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